GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lunit 328130.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

16,170

+4.66%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2024

Revenue

₩17.46bn

FY2019FY2024

Net income

₩498.7m

FY2019FY2024

Free cash flow

−₩2.13bn

FY2019FY2024

Shareholders' equity

₩6.47bn

FY2019FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019
Revenue₩17.46bn₩10.13bn₩8.33bn₩6.64bn₩1.43bn₩198.4m
Research and development₩835.2m₩553.5m₩328.7m₩22.30bn₩9.06bn—
Operating income₩545.3m−₩1.03bn₩48.2m−₩45.70bn−₩20.95bn−₩11.60bn
Net income₩498.7m−₩827.8m₩72.8m−₩73.68bn−₩83.74bn−₩46.97bn
Diluted earnings per share1.20-2.010.19-3,274.55-3,840.90-4,465.07

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019
Total assets₩16.90bn₩13.68bn₩8.96bn₩93.85bn₩25.12bn₩38.41bn
Cash and short-term investments₩1.18bn₩1.20bn₩2.47bn₩86.72bn₩20.94bn₩36.57bn
Total liabilities₩10.43bn₩7.66bn₩2.33bn₩91.81bn₩155.76bn₩97.29bn
Debt₩7.77bn₩5.35bn₩1.34bn₩939.6m₩32.28bn—
Shareholders' equity₩6.47bn₩6.02bn₩6.64bn₩2.04bn−₩130.64bn−₩58.87bn
Shares outstanding416m413m383m22m22m11m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−₩1.19bn−₩2.80bn−₩326.4m−₩32.72bn−₩16.75bn−₩10.00bn
Capital spending−₩943.5m−₩499.0m−₩333.2m−₩753.1m−₩845.7m−₩415.9m
Free cash flow−₩2.13bn−₩3.30bn−₩659.5m−₩33.48bn−₩17.60bn−₩10.42bn
Dividends paid−₩366.7m−₩75.3m−₩226.3m———

Financial ratios

Data as of 29 Aug 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin-100.0%-135.0%-168.3%-365.3%-1076.8%——
Net margin-57.0%-152.1%-146.7%-282.1%-1109.7%-5855.7%—
Return on equity-34.5%-50.0%-15.7%-56.8%-3615.8%64.1%—
Return on assets-12.8%-18.9%-13.7%-40.3%-78.5%-333.3%—
Revenue growth53.4%116.0%80.9%108.9%364.3%620.8%—
Earnings growth-42.5%124.0%-5.9%-46.9%-12.0%78.3%—
Current ratio0.26x0.44x18.01x7.20x1.02x0.14x—
Debt to equity——0.00x0.00x0.00x0.00x0.00x
Equity ratio37.2%37.9%87.8%70.9%2.2%-520.0%—
Interest coverage-3.23x-5.34x-21.00x-42.62x-30.67x——
R&D as a share of sales50.2%50.3%66.3%132.4%335.9%633.4%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue38.0%144.9%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-1.8%-108.4%-178.1%—
Net margin-1.2%-173.7%-463.1%—

Valuation history

At each fiscal year end

FY2023FY2022
Price to earnings-20907.3—
Price to sales—337.8

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 2543-for-2378 split · 18 Mar 2026
  • 2-for-1 split · 9 Nov 2023
  • 647-for-623 split · 22 Sept 2023

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.